脑转移中的 TKI 抗药性：CTLA4 状态

IF 25.5 1区医学 Q1 IMMUNOLOGY

Immunity Pub Date : 2024-11-12 DOI:10.1016/j.immuni.2024.10.009

Elena Donders, Diether Lambrechts

引用次数: 0

摘要

肺癌脑转移（LCBM）患者对酪氨酸激酶抑制剂（TKIs）的耐药性仍然是一项临床挑战。最近，Fu 等人在《癌症细胞》（Cancer Cell）杂志上揭示了酪氨酸激酶抑制剂如何重塑 LCBM 的免疫微环境，并提出 CTLA4 阻断是克服耐药性的一种有前途的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TKI resistance in brain metastasis: A CTLA4 state of mind

Resistance to tyrosine kinase inhibitors (TKIs) in lung cancer brain metastasis (LCBM) remains a clinical challenge. Recently in Cancer Cell, Fu et al. reveal how TKIs reshape the immune microenvironment of LCBM and propose CTLA4 blockade as a promising strategy to overcome resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunity 医学-免疫学

CiteScore

49.40

自引率

2.20%

发文量

205

审稿时长

6 months

期刊介绍： Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.